South San Francisco-based Global Blood Therapeutics struck a deal with Syros Pharmaceuticals that is worth up to $375 million to discover, develop and commercialize novel therapies for the two types of blood disorders.
The U.S. FDA approved Celgene and Acceleron Pharma’s Reblozyl for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Relying on the trickery used by the AIDS virus to infect people, doctors at two medical centers say they have cured 10 infants of so-called bubble boy disease, a genetic defect that leaves children (typically boys) without an immune system.
